Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database

Previous cost-effectiveness analyses (CEAs) of abiraterone for castration-resistant prostate cancer (CRPC) patients have not shown favorable results for this new drug. These CEAs were generally conducted based on models used in clinical trials, where comparisons were made with patients given placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunisawa, Susumu, Tange, Chihiro, Shimozuma, Kojiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628043/
https://www.ncbi.nlm.nih.gov/pubmed/26543759
http://dx.doi.org/10.1186/s40064-015-1413-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628043/
https://www.ncbi.nlm.nih.gov/pubmed/26543759
http://dx.doi.org/10.1186/s40064-015-1413-9

Ejemplares similares